Divalproex Sodium Tablet, Film Coated, Extended Release
Product Images NDC 51079-767

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Divalproex Sodium (NDC 51079-767). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Mylan Institutional Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Divalproex Sodium Extended-release 250 mg Tablets Unit Carton Label (Image 01)

Divalproex Sodium Extended-Release Tablets, USP, are a prescription medication used for once-daily dosing of valproic acid activity. Each film-coated tablet contains 1250mg of divalproex sodium, USP. It is recommended to refer to accompanying prescribing information and medication guide for usual dosage. Manufactured by Mylan Pharmaceuticals Inc., it should be stored at 20° to 25°C (68° to 77°F) with USP controlled room temperature.*

FDA Label Image

Divalproex Sodium 500 mg Tablets Unit Carton Label (Image 02)

This is a medication package designed for institutional use only and is not child-resistant. It is important to keep this and all drugs out of reach of children. The container is designed to resist light. The package also provides information on the lot number and expiration date. The manufacturer of the medication is Mylan, located in Rockford, IL, USA.*

FDA Label Image

Divalproex Structural Formula (Image 03)

FDA Label Image

Figure 1: Proportion Of Patients Achieving Any Particular Level Of Improvement Was Consistently Higher For Valproate Than For Placebo (Image 04)

This text appears to be a graph or chart showing the "Reduction in CP$ Rate" with percentages of patients receiving improvement, no change, or worsening as a result. Unfortunately, without more context, it is difficult to determine the specific details and meaning of the chart.*

FDA Label Image

Figure 2: Proportion Of Patients (x Axis) Whose Percentage Reduction From Baseline In Complex Partial Seizure Rates Was At Least As Great As That Indicated On The Y Axis In The Monotherapy Study (Image 05)

This seems to be a diagram or chart showing the percentages of patients on different doses of a medication called Divalroex Sodium, with variations in the release of the medication. The chart shows three different options: high dose delayed release, low dose delayed release, and no change. The percentages range from 0-50% for each option. There are also symbols indicating increase or decrease in percentage from the previous row. However, it is not possible to provide more information or context without further details.*

FDA Label Image

Figure 3: Mean Reduction In 4-week Migraine Headache Rates (Image 06)

FDA Label Image

Unit Carton (Image 07)

This is a product description for Divalproex Sodium Extended-Release Tablets, which are used for once-daily dosing to treat Valproic Acid Activity. The tablets are film-coated and contain 500mg of valproic acid. The recommended dosage is not mentioned, so one needs to refer to the accompanying prescribing information for that. Also, the tablets should be stored at 20°C to 25°C, and the manufacturer is Mylan Pharmaceuticals Inc.*

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.